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Abstract
Arboviruses are medically important pathogens that cause human disease ranging from a mild 
fever to encephalitis. Laboratory diagnosis is essential to differentiate arbovirus infections from 
other pathogens with similar clinical manifestations. The Arboviral Diseases Branch (ADB) 
reference laboratory at the CDC Division of Vector-Borne Diseases (DVBD) produces reference 
antigens used in serological assays such as the virus-specific immunoglobulin M antibody-capture 
enzyme-linked immunosorbent assay (MAC-ELISA). Antigen production in cell culture has 
largely replaced the use of suckling mice; however, the methods are not directly transferable. The 
development of a cell culture antigen production algorithm for nine arboviruses from the three 
main arbovirus families, Flaviviridae, Togaviridae, and Bunyaviridae, is described here. Virus cell 
culture growth and harvest conditions were optimized, inactivation methods were evaluated, and 
concentration procedures were compared for each virus. Antigen performance was evaluated by 
the MAC-ELISA at each step of the procedure. The antigen production algorithm is a framework 
for standardization of methodology and quality control; however, a single antigen production 
protocol was not applicable to all arboviruses and needed to be optimized for each virus.
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1. Introduction
There are over 500 arthropod-borne viruses, or arboviruses, geographically distributed 
throughout the world, over 150 of which cause disease in human and/or animal populations 
(Burke, Monath, 2001; Centers for Disease Control and Prevention, 2014; Cleton et al., 
2012; Gubler, 2002; Monath, Heinz, 1996; Rosenberg et al., 2013; Weaver, 2005). Some 
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arboviruses, such as dengue, Japanese encephalitis, and most recently chikungunya (CHIK) 
viruses, have wide geographical distribution and cause large seasonal epidemics (Powers et 
al., 2000; Staples et al., 2009). Others, such as West Nile virus, Zika virus and again, CHIK 
virus, are emerging or reemerging, and may cause sporadic outbreaks in regions in which 
they were not previously detected (Lanciotti et al., 1999; Lanciotti et al., 2007; Lanciotti et 
al., 2008; Solomon, Winter, 2004). Other arboviruses, such as Powassan (POW), have low 
or unknown incidence, and may be detected due to emergence or increased surveillance (Ei 
Khoury et al., 2013).
Arbovirus infections may present with clinical symptoms similar to those of other bacterial 
or virological infections, such as an influenza-like illness, encephalitis, or polio-like myelitis 
(Burke, Monath, 2001). In addition, arboviruses within a serocomplex may cause similar 
disease syndromes and may be clinically indistinguishable from one another. Laboratory 
diagnosis is necessary to identify arbovirus infections and differentiate between other 
bacterial or viral pathogens, particularly if there is an effective treatment or vaccine 
available. Although detection of viral RNA or virus isolation is the gold standard for 
diagnosis and identification of a viral infection, these methods are not sensitive in many 
arbovirus infections due to the brief, transient, low-level viremia (≤100 infectious 
particles/ml) that may be cleared by the onset of illness. The virus-specific immunoglobulin 
M (IgM) antibody-capture enzyme-linked immunosorbent assay (MAC-ELISA) can be used 
for rapid detection of acute arbovirus infections, as IgM antibody is produced early in 
infection, rises rapidly to detectable levels, and is less cross-reactive than IgG antibodies 
(Johnson et al., 2000; Johnson et al., 2005; Martin et al., 2000; WHO, 2003; Wong et al., 
2003; Wong et al., 2004). The CDC Division of Vector-Borne Diseases (DVBD) Arboviral 
Diseases Branch (ADB) reference laboratory produces antigens for the MAC-ELISA for a 
wide array of arboviruses, most of which are not available commercially.
Viral antigen used in serological assays was previously generated from sucrose-acetone 
extracted suckling mouse brain (SMB) preparations. In order to reduce the use of animals, 
viral antigen production has shifted towards cell culture. This has necessitated modification 
and optimization of the methods previously used during SMB antigen production to cell 
culture, such as virus inactivation and concentration. The development of a cell culture 
antigen production algorithm for nine arboviruses from the three main arbovirus families, 
Flaviviridae, Togaviridae, and Bunyaviridae, is reported here. Cell culture conditions and 
inactivation and concentration procedures were optimized for each virus, using the MAC-
ELISA as the performance indicator.
2. Materials and Methods
2.1. Viruses
Yellow Fever virus (YFV) strain 17D; St. Louis Encephalitis virus (SLEV) strain TBH-28; 
Powassan virus (POWV) strain LB; Chikungunya virus (CHIKV) strains 181/25 and S27; 
Mayaro virus (MAYV) strain TR15537; Sindbis virus (SINV) strains EgAr 339, 16260, 80–
2449, AUS C 263, AUS C 377, AUS MRM 39, INDA 1036, MAL AMM 2215, 
Michalovce, Reed Warbler, SAAR 86 and UGMP 684; La Crosse virus (LACV) strain 
Original; Jamestown Canyon virus (JCV) strains 61V-2235 and MN256–260; and Tahyna 
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virus (TAHV) strain Bardos 92 were obtained from the Arbovirus Reference Collection at 
the Centers for Disease Control and Prevention (CDC), Division of Vector-Borne Diseases 
(DVBD) in Fort Collins, Colorado.
2.2. Tissue culture
Cell lines used in the growth curves were obtained at CDC DVBD. African green monkey 
kidney (Vero) cells, baby hamster kidney (BHK-21) clones 13 and 15 cells, rhesus monkey 
kidney (LLC-MK2) cells, and Vero clone E6 cells were maintained at 37°C in Dulbecco’s 
Modified Eagle Medium (DMEM, Life Technologies, Grand Island, NY) with 8% fetal 
bovine serum (FBS, Atlas Biologicals, Fort Collins, CO), 1mM sodium pyruvate (Life 
Technologies), 27mM sodium bicarbonate (Life Technologies), 0.1mM gentamicin (Lonza, 
Walkersville, MD), and 1uM amphotericin B (Sigma-Aldrich, St. Louis, MO). Aedes 
albopictus mosquito C6/36 cells were maintained at 28°C in DMEM (Life Technologies) 
with 10% FBS (Atlas Biologicals), 0.1mM non-essential amino acids (Life Technologies), 
1mM sodium pyruvate (Life Technologies), 9mM sodium bicarbonate (Life Technologies), 
and 0.1mM gentamicin (Lonza).
2.3. Growth curves
Growth curves were performed in T150 cm2 cell culture flasks (Corning Inc. Life Sciences, 
Tewksbury, MA) at a multiplicity of infection (MOI) ranging from 0.0005 to 0.1 plaque-
forming units (PFU)/cell. Following adsorption of virus in 10 ml of media at 37°C for 1 h, 
cells were maintained in 60 ml of their respective media as described above, albeit with 2% 
FBS (Atlas Biologicals). At 24 h intervals, 0.5–1.0 ml of supernatant was removed and 
frozen at −70°C until tested. Growth curves were carried out for 3 to 16 days until 
cytopathic effect (CPE) reached ∼90–100%, or until the cells became overgrown in the 
negative control flask.
2.4. Virus titration
Virus titers were determined by 1% agarose double-overlay plaque titration assay in Vero 
cells, as previously described (Beaty et al., 1995). Plaques were visualized with second 
overlays applied with 0.005% neutral red (Sigma-Aldrich) following incubation for 2 days 
for CHIKV, MAYV, SINV, LACV, and TAHV; 3 days for JCV; 4 days for YFV; and 6 
days for SLEV and POWV. Virus titers were recorded as log10 PFU/ml.
2.5. IgM antibody-capture enzyme-linked immunosorbent assay (MAC-ELISA)
Viral antigen activity was evaluated by the CDC MAC-ELISA, as previously described 
(Martin et al., 2000). Live virus or inactivated antigen was serially diluted two-fold and 
reacted against both constant IgM positive and normal control sera, obtained from the 
DVBD diagnostic laboratory, except the SINV IgM positive control, for which no human 
sera was available. An alphavirus-group reactive mouse/human chimeric monoclonal 
antibody (cMAb) served as the SINV IgM positive control (Thibodeaux et al., 2011). Virus-
specific antigen activity (VSAA) was defined as the optical density (OD) of viral antigen 
reacted against a constant positive control serum; acceptable VSAA had an OD of >0.8. 
Nonspecific background reactivity (NBR) was defined as the OD of viral antigen reacted 
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against a constant normal control serum; acceptable NBR had an OD of <0.2. A satisfactory 
antigen was defined as that which had acceptable MAC-ELISA results, in which both the 
VSAA and NBR were within acceptable OD ranges; the highest antigen dilution with 
acceptable VSAA and NBR OD ranges was considered the working antigen dilution, and 
was a measure of functional antigen concentration.
2.6. Virus production for inactivation and concentration analyses
The optimal virus strain, cell type, and day of harvest were determined by the growth curves 
from one T150 cm2 flask, after which a second batch was made in additional T150 cm2 
flask(s) under the optimized conditions. Supernatant was harvested, with volumes ranging 
from 60 to 500 ml, clarified at 2400 x g for 10 min at 4°C, and stored at −70°C with 20% 
FBS (Atlas Biologicals) until further analysis. Flaviviruses grow relatively slowly and it was 
possible to collect and replenish supernatant on multiple days from one flask. The harvests 
were then combined to make one batch.
2.7. Virus inactivation methods
2.7.1. Beta-propiolactone (BPL)—Cell culture supernatants were thawed in a 44°C 
water bath with intermittent shaking, treated with BPL (CTC Organics, Atlanta, GA) at final 
concentrations ranging from 0.01% to 0.3%, and incubated for 24 h at 4°C with moderate 
shaking on a refrigerated shaker plate. Mock-treated control supernatants (no addition of 
BPL) were incubated under the same conditions as the BPL-treated samples. Due to acidic 
BPL by-products, 7.5% sodium bicarbonate (Life Technologies) was added intermittently to 
adjust the pH (French, McKinney, 1964). Following BPL treatment the samples were stored 
at −70°C until further analysis. For hydrolysis analysis, samples were treated with 0.05 or 
0.3% BPL and incubated for 48 h at 4°C with moderate shaking. Following BPL treatment, 
samples that underwent hydrolysis were incubated at 37°C for 2 h, then placed at −70°C 
until further analysis.
2.7.2. Gamma-irradiation—Gamma-irradiation using a cobalt-60 source was carried out 
at the CDC irradiation facility in Atlanta, GA. Small volume aliquots of virus were 
irradiated with doses ranging from1–6 Mrad in a “kill curve.” All material was maintained 
frozen on dry ice throughout the treatment process. Untreated control supernatants remained 
frozen without any exposure to gamma-irradiation.
2.7.3. Gamma-irradiation + BPL—Virus supernatant was treated with 5.5 to 6 Mrad, 
thawed, concentrated 5X to 6X with Centricon Plus-70 100kDa Centrifugal Filter Devices 
(Millipore), and then treated with BPL at final concentrations ranging from 0.01% to 0.1%.
2.7.4. 37% Formaldehyde (Formalin)—Cell culture supernatants were treated with 
0.05% to 0.3% final concentrations of 37% formalin (Fisher Scientific, Waltham, MA) and 
incubated for 4.5 days at 4°C, room temperature, or 37°C with moderate shaking or stirring 
(Sabin, 1943). Aliquots were taken at 6, 12, 24, 36, 48, 72, 96, and 108 h and tested for 
antigen activity.
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2.7.4. Hydrogen peroxide—Cell culture supernatants were treated with a 3% final 
concentration of hydrogen peroxide (Fisher Scientific) and incubated for 2 h at room 
temperature with moderate shaking, as described (Amanna et al., 2012). To adjust for pH 
changes, 7.5% sodium bicarbonate (Life Technologies) was added intermittently during 
incubation.
2.7.5. N-Lauroylsarcosine sodium salt (Sarkosyl)—Cell culture supernatants were 
treated with 0.1% to 0.3% final concentrations of sarkosyl (Sigma-Aldrich) and incubated 
for 1 h at room temperature, as previously described (Piret et al., 2002a, 2002b). Prior to 
treatment, the sarkosyl stock solution was filtered through a Millex GV PVDF 0.22-µm 
membrane (Millipore, Billerica, MA) for sterilization purposes.
2.8. Antigen Concentration Methods
2.8.1. Ultracentrifugation—Inactivated cell culture supernatants were concentrated by 
ultracentrifugation at 54,000 x g at 4°C for ∼16 h. Supernatant was completely removed and 
pelleted antigen was resuspended in 0.1M trizma/BS buffer: 1.0M trizma pH 9.0 (Sigma-
Aldrich) + borate saline solution pH 9.0 [1.5M sodium chloride (Daigger, Vernon Hills, IL), 
0.5M boric acid (Fisher Scientific), 1.0N sodium hydroxide (Daigger)], or 1X phosphate 
buffered saline (PBS, Life Technologies) to achieve the desired concentration factor.
2.8.2. Centrifugal filters—Inactivated cell culture supernatants were concentrated in 
Amicon Ultra-15 100-kDa Centrifugal Filter Devices (Millipore) or Centricon Plus-70 100-
kDa Centrifugal Filter Devices at 3500 x g for 10–45 min at 4°C. Any material that was 
inadvertently concentrated beyond the desired concentration factor was diluted to the correct 
volume with 0.1M trizma/BS buffer or 1X PBS.
2.9. Infectivity assays
Two methods were used to evaluate infectivity of inactivated antigen as described 
previously with modifications (Monath et al., 2010). Briefly, plaque titration of the treated 
antigen material was performed in duplicate in 6-well plates on Vero cells, beginning at neat 
concentration. In addition, 100 µl of treated antigen was inoculated into duplicate T25 cm2 
cell culture flasks containing Vero or BHK-21c.15 cells and passaged once a week for 3 
weeks. Virus was considered inactivated if there was no detectable titer by plaque titration 
and if there was no detectable CPE in any of the three cell culture passages.
3. Results
3.1. Growth curves
Virus growth curves were performed first to determine the optimal virus strain and cell 
culture type to use for subsequent antigen production. Viruses were inoculated into T150 
cm2 flasks at MOIs ranging from 0.0005 to 0.1 and incubated for 3 to 16 days, depending on 
CPE and the condition of the cell monolayer. Supernatant, 0.5–1 ml, was removed at 24 h 
time points and tested by plaque titration and/or MAC-ELISA. The growth and harvest 
conditions resulting in the highest titer and/or greatest acceptable antigen activity were 
chosen to make a second batch, which was used in the inactivation and concentration 
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analyses. If multiple conditions generated the highest titer and/or greatest acceptable antigen 
activity equally (e.g. POWV produced from Vero and BHK-21 cells both generated the 
highest VSAA), the cell culture that yielded more product (as in performing multiple 
collections), was chosen. Second-batch product was evaluated by MAC-ELISA to confirm 
acceptable VSAA and NBR ranges prior to inactivation experiments; the results are shown 
in Table 1 (untreated).
3.1.1. Flaviviruses
Yellow Fever Virus: YFV strain 17D was inoculated into Vero and BHK-21c.15 cells at an 
MOI of 0.01 and incubated for 8 days. YFV grown in Vero cells had the highest titer of 8.3 
log10 PFU/ml at day 4 (Figure 1A). The second batch of YFV was grown in Vero cells and 
supernatant was replaced and harvested on days 4, 5, and 6 and the three collections were 
combined into one batch. The VSAA and NBR of YFV were acceptable and the working 
antigen dilution was 1:32 (Table 1A, untreated).
St. Louis Encephalitis virus: SLEV strain TBH-28 was inoculated at an MOI of 0.01 into 
Vero, BHK-21c.13, and BHK-21c.15 cells, and at an MOI of 0.1 into Vero cells. BHK-21c.
13 and BHK-21.15 cells were incubated for 4 days and Vero cells were incubated for 11 
days. Titers of approximately 7 log10 PFU/ml were similar in Vero (MOI = 0.1) and 
BHK-21c.13 cells at day 3 (Figure 1B). Vero cells (MOI = 0.1) were selected for second 
batch production, and supernatant was replaced and harvested on days 3 and 4 and combined 
into one batch. The VSAA and NBR of SLEV were acceptable and the working antigen 
dilution was 1:8 (Table 1B, untreated).
Powassan virus: POWV strain LB was inoculated at an MOI of 0.01 and incubated for 16 
days in Vero and LLC-MK2 cells and for 4 days in BHK-21c.13 and BHK-21c.15 cells. 
Peak titers of approximately 8 log10 PFU/ml were similar in Vero cells at days 6–9 and in 
BHK-21c.13 cells at day 2 (Figure 1C). Time point aliquots were also tested by the POWV 
MAC-ELISA to determine peak VSAA. POWV produced from Vero cells and collected on 
day 6 yielded higher VSAA compared to those obtained from BHK-21c.13, BHK-21c.15, 
and LLC-MK2 cells (working antigen dilutions of 1:32, unusable, unusable, and 1:8, 
respectively), and was therefore selected for second batch production, with supernatant 
replaced and harvested on days 5, 6, and 7 and combined into one batch. The VSAA and 
NBR were acceptable and the working antigen dilution was 1:16 (Table 1C, untreated).
3.1.2. Alphaviruses
Chikungunya virus: CHIKV strains 181/25 and S27 were inoculated into Vero and 
BHK-21c.15 cells at an MOI of 0.001 and incubated for 4 days, and into C6/36 cells at an 
inadvertent MOI of 0.0005 and incubated for 5 days. Peak titers were between 8 and 10 
log10 PFU/ml in all cell types (Figure 1D). Time point aliquots tested by the CHIKV MAC-
ELISA showed variation in the VSAAs, which did not correspond to the titers. 
Representative CHIKV titer and MAC-ELISA results are shown in Table 2. CHIKV strain 
181/25 grown in C6/36 cells and CHIKV strain S27 grown in BHK-21c.15 cells were the 
only two preparations to yield both acceptable VSAA and NBR; other CHIKV strain/cell 
type combinations yielded VSAA below the acceptable range, despite the high titers (Figure 
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1D). CHIKV strains 181/25 and S27 were both grown in C6/36 cells and had equivalent 
titers of 10.3 log10 PFU/ml, but only strain 181/25 had acceptable VSAA. CHIKV strain 
S27 grown in Vero and BHK-21c.15 cells had nearly equivalent titers of 9.4 and 9.3 log10 
PFU/ml, respectively; however, only strain S27 grown in BHK-21c.15 cells had acceptable 
VSAA. Second batches were produced from CHIKV strain 181/25 grown in C6/36 cells and 
harvested on day 3 and CHIKV strain S27 grown in BHK-21c.15 cells and harvested on day 
2: the VSAAs and NBRs were acceptable and the working antigen dilutions were 1:32 and 
1:4, respectively (Table 1D, untreated).
Mayaro virus: MAYV strain TR15537 was inoculated into Vero, BHK-21.c13, and 
BHK-21c.15 cells at an MOI of 0.001 and incubated for 5 days. Peak titers were 
approximately equivalent at 9 log10 PFU/ml in all cell types at day 2 (Figure 1E). Aliquots 
were also tested by the MAYV MAC-ELISA. MAYV grown in BHK-21c.15 cells and 
collected on day 2 yielded higher VSAA over those obtained from Vero and BHK-21c.13 
cells (working antigen dilutions of 1:8, neat, and 1:2, respectively), and was therefore 
selected for production of the second batch. MAYV harvested on day 2 from BHK-21c.15 
cells had acceptable VSAA and NBR and yielded a working antigen dilution of 1:4 (Table 
1E, untreated).
Sindbis virus: SINV strain EgAr 339 was inoculated into Vero, BHK-21c.13, BHK-21c.15, 
and LLC-MK2 cells at an MOI of 0.001 and incubated for 4 days. Peak titers were >7 log10 
PFU/ml by day 2 in all cell types except LLC-MK2 (Figure 1F). However, none of the 
aliquots tested by the SINV MAC-ELISA yielded acceptable VSAAs (data not shown).
Therefore, additional SINV strains (16260, 80–2449, AUS C 263, AUS C 377, AUS MRM 
39, INDA 1036, MAL AMM 2215, Michalovce, Reed Warbler, SAAR 86, and UGMP 684) 
were inoculated into Vero, BHK-21c.13, and BHK-21c.15 cells at an MOI of 0.001 and 
supernatant was collected only on day 2. In this instance, the day 2 aliquots were first tested 
by the SINV MAC-ELISA to determine if any strain yielded acceptable VSAA. SINV strain 
AUS MRM 39 produced from Vero and BHK-21c.13 cells were the only two preparations to 
yield acceptable VSAAs (working antigen dilutions of 1:10 for both). Subsequently, titer 
was determined only for the day 2 aliquot of SINV strain AUS MRM 39 produced from 
Vero cells (Figure 1F), and SINV strain AUS MRM 39 was selected for second batch 
production. SINV strain AUS MRM 39 harvested on day 2 from Vero cells had acceptable 
VSAA and NBR and yielded a working antigen dilution of 1:8 (Table 1F, untreated).
3.1.3. Bunyaviruses
La Crosse virus: LACV strain Original was inoculated into Vero, BHK-21.c13, and 
BHK-21c.15 cells at an MOI of 0.01 and incubated for 4 days. Peak titers were 
approximately equivalent at 8 log10 PFU/ml at day 2 (Figure 1G). All time point aliquots 
were tested by the LACV MAC-ELISA. LACV grown in BHK-21c.13 cells and collected 
on day 3 yielded higher VSAA over those obtained from Vero and BHK-21c.15 cells 
(working antigen dilutions of 1:160, 1:4, and 1:40, respectively), and was therefore selected 
for production of the second batch. LACV grown in BHK-21c.13 cells and harvested on day 
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3 had acceptable VSAA and NBR and yielded a working antigen dilution of 1:80 (Table 1G, 
untreated).
Jamestown Canyon virus: JCV strain 61V-2235 was inoculated at an MOI of 0.01 and 
incubated for 4 days in BHK-21c.13 and Vero E6 cells and for 5 days in Vero, BHK-21c.15, 
and LLC-MK2 cells. Additionally, JCV strain MN256–260 was inoculated into BHK-21c.13 
cells at an MOI of 0.01 and supernatant was collected only on day 3. Peak titers ranged from 
7–9 log10 PFU/ml at days 2–3 (Figure 1H). Time point aliquots were also tested by the JCV 
MAC-ELISA. JCV strain MN256–260 grown in BHK-21c.13 cells and collected on day 3 
yielded higher VSAA over JCV strain 61V-2235 obtained from Vero, Vero E6, BHK-21c.
13, BHK-21c.15, and LLC-MK2 cells (working antigen dilutions of 1:32, unusable, 
unusable, 1:16, 1:8, and unusable, respectively), and was therefore selected for production of 
the second batch. JCV strain MN256–260 harvested on day 3 from BHK-21c.13 cells had 
acceptable VSAA and NBR and yielded a working antigen dilution of 1:32 (Table 1H, 
untreated).
Tahyna virus: TAHV strain Bardos 92 was inoculated into Vero, BHK-21.c13, and 
BHK-21c.15 cells at an MOI of 0.01 and incubated for 4 days. Peak titers ranged from 7.5–
8.5 log10 PFU/ml at day 2 (Figure 1I). Time point aliquots were also tested by the TAHV 
MAC-ELISA. TAHV grown in BHK-21c.13 cells and collected on day 3 yielded higher 
VSAA over those obtained from Vero and BHK-21c.15 cells (working antigen dilutions of 
>1:32, 1:4, and 1:32, respectively), and was therefore selected for production of the second 
batch. TAHV harvested on day 3 from BHK-21c.13 cells had acceptable VSAA and NBR 
and yielded a working antigen dilution of 1:40 (Table 1I, untreated).
3.2. Virus inactivation
Five inactivation methods were evaluated. Viruses were successfully inactivated by BPL, 
gamma-irradiation, or a combination of gamma-irradiation followed by BPL. YFV, SLEV, 
POWV, LACV, JCV, and TAHV were treated with 0.01, 0.025, 0.05, 0.075, and 0.1% BPL, 
and CHIKV, MAYV, and SINV were treated with 0.1, 0.15, 0.2, 0.25, and 0.3% BPL. YFV, 
SLEV, and CHIKV strain S27 were irradiated with 1–5 Mrad, and CHIKV strain 181/25, 
MAYV, and SINV were irradiated with 1–6 Mrad. For the combination gamma-
irradiation/BPL treatments, CHIKV strain S27 and MAYV strain TR15537 were irradiated 
with 5.5 and 6 Mrad, respectively, concentrated, and then treated with 0.01, 0.025, 0.05, 
0.075, and 0.1% BPL. Representative results are shown in Table 1.
Inactivated antigen was evaluated in the MAC-ELISA, and rated as acceptable or 
unacceptable based on VSAA and NBR. Plaque titration and passage three times in cell 
culture was used to rule out residual infectivity. The chosen inactivation method was the one 
that completely inactivated the virus, had VSAA and NBR within the acceptable ranges, and 
had the highest working antigen dilution compared to the mock-treated or untreated virus. 
Inactivated virus was then concentrated to a standardized working dilution of ∼1:160 and 
re-evaluated in the MAC-ELISA and infectivity assays.
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3.2.1. Yellow fever virus—Unconcentrated YFV treated with ≤0.05% BPL yielded 
acceptable MAC-ELISA results (Table 1A), but was infectious at 0.01% BPL. In addition, 
after concentration, the NBR of antigen treated with 0.025 and 0.05% BPL rose above the 
acceptable limit. Unconcentrated YFV treated with gamma-irradiation also yielded 
acceptable MAC-ELISA results, but was infectious at ≤4 Mrad. Concentrated antigen 
inactivated with 5 Mrad had acceptable MAC-ELISA results, was non-infectious, and was 
therefore selected as the inactivation method for final, scaled-up YFV antigen production.
3.2.2. St. Louis encephalitis virus—Unconcentrated SLEV treated with ≤0.1% BPL 
yielded acceptable MAC-ELISA results (Table 1B); however, antigen treated with 0.01% 
BPL was infectious. Concentrated antigen inactivated with ≥0.05% BPL had acceptable 
MAC-ELISA results and remained non-infectious. Unconcentrated SLEV treated with 
gamma-irradiation yielded acceptable MAC-ELISA results, but was infectious at ≤4 Mrad. 
Concentrated antigen inactivated with 5 Mrad had acceptable MAC-ELISA results and was 
non-infectious. Due to the ease of use of BPL over gamma-irradiation, inactivation with 
0.05% BPL was selected for final, scaled-up SLEV antigen production.
3.2.3. Powassan virus—Unconcentrated POWV treated with ≤0.1% BPL yielded 
acceptable MAC-ELISA results (Table 1C), but was infectious at 0.01% BPL. Concentrated 
antigen inactivated with ≥0.05% BPL had acceptable MAC-ELISA results and remained 
non-infectious. Inactivation with 0.05% BPL was selected for final, scaled-up POWV 
antigen production.
3.2.4. Chikungunya virus—The VSAA of unconcentrated CHIKV strain 181/25 
increased after BPL treatment compared to mock-treated virus, which had a VSAA below 
the acceptable limit (Table 1D). The greatest increase was after 0.1% BPL treatment, with 
the VSAA decreasing as the BPL concentration increased to 0.3%. All BPL concentrations 
completely inactivated the virus; however, after concentration, the NBRs rose above the 
acceptable limit. The VSAA of unconcentrated CHIKV strain 181/25 treated with ≥4 Mrad 
also increased compared to the untreated virus and yielded acceptable MAC-ELISA results, 
but all gamma-irradiated samples were infectious.
VSAAs of unconcentrated CHIKV strain S27 increased as gamma irradiation doses 
increased (Table 1D), but similar to CHIKV strain 181/25, all samples were infectious. As 
neither BPL nor gamma-irradiation treatment alone completely inactivated CHIKV, CHIKV 
strain S27 was treated with a combination of gamma-irradiation followed by BPL. CHIKV 
strain S27 was irradiated with 5.5 Mrad, concentrated, and then treated with ≤0.1% BPL 
(Table 1D). The combination treatment of 5.5 Mrad plus ≤0.05% BPL produced acceptable 
MAC-ELISA results and was non-infectious; therefore, inactivation with 5.5 Mrad + 0.01% 
BPL (the lowest dose) was selected for final, scaled-up CHIKV antigen production.
3.2.5. Mayaro virus—Unconcentrated MAYV treated with ≤0.2% BPL yielded 
acceptable MAC-ELISA results (Table 1E) and was non-infectious. Similar to CHIKV, the 
VSAA of MAYV increased after 0.1% BPL treatment compared to mock-treated MAYV 
and decreased as the BPL concentration increased to 0.3%. Concentrated antigen treated 
with ≥ 0.15% BPL produced acceptable MAC-ELISA results and was non-infectious, but at 
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0.1% BPL remained infectious. Unconcentrated MAYV treated with gamma-irradiation also 
yielded acceptable MAC-ELISA results, with increased VSAA as Mrads increased, but was 
infectious at all doses. MAYV was inactivated by a combination of gamma-irradiation 
followed by BPL. Unconcentrated MAYV was irradiated with 6 Mrad, concentrated, and 
then treated with ≤0.1% BPL (Table 1E), with 6 Mrad and ≤0.05% BPL yielding acceptable 
MAC-ELISA and non-infectivity results.
Scale-up production of MAYV antigen with inactivation by 6 Mrad + 0.01% BPL was 
performed prior to inactivation with BPL. However, due to the ease of use of BPL over the 
gamma-irradiation/BPL combination, inactivation with 0.15 or 0.2% BPL could be used for 
future MAYV antigen production.
3.2.6. Sindbis virus—Unconcentrated SINV treated with ≤0.3% BPL yielded acceptable 
MAC-ELISA results (Table 1F), and was non-infectious. Concentrated antigen treated with 
≥0.15% BPL produced acceptable MAC-ELISA results and remained non-infectious, but at 
0.1% BPL remained infectious. Unconcentrated SINV treated with gamma-irradiation also 
yielded acceptable MAC-ELISA results, with VSAA increasing as Mrads increased, but was 
infectious at ≤5 Mrad. Concentrated antigen inactivated with 6 Mrad produced acceptable 
MAC-ELISA results and remained non-infectious. Due to the ease of use of BPL over 
gamma-irradiation, inactivation with 0.25% BPL was selected for final, scaled-up SINV 
antigen production.
3.2.7. La Crosse virus antigen—Unconcentrated and concentrated LACV antigen 
treated with ≤0.1% BPL yielded acceptable MAC-ELISA results (Table 1G), and was non-
infectious. Additionally, VSAA increased after BPL treatment compared to mock-treated 
virus, and increased as the BPL concentration increased. Treatment with 0.1% BPL was 
selected for final, scaled-up LACV antigen production.
3.2.8. Jamestown Canyon virus antigen—Unconcentrated and concentrated JCV 
antigen treated with ≤0.1% BPL yielded acceptable MAC-ELISA results (Table 1H), and 
was non-infectious. Even though concentrated 0.01% BPL-treated JCV material produced 
the highest VSAA and remained non-infectious during small-scale production, 0.05% BPL 
was selected for final, scaled-up JCV antigen production to assure that the scale-up material 
was completely inactivated, as 0.01% BPL had been shown to be ineffective at inactivating 
the flaviviruses. Also, the working antigen dilution could be adjusted by the concentration 
factor.
3.2.9. Tahyna virus antigen—Unconcentrated and concentrated TAHV treated with 
≤0.05% BPL yielded acceptable MAC-ELISA results (Table 1I), and was non-infectious. 
Similar to JCV, concentrated 0.01% BPL-treated TAHV material produced the highest 
VSAA and remained non-infectious during small-scale production, but 0.05% BPL was 
selected for final, scaled-up TAHV antigen production to assure complete inactivation.
3.2.10. Virus inactivation with formalin, hydrogen peroxide, and sarkosyl—
YFV was treated with formalin at final concentrations ranging from 0.05% to 0.3%. The 
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MAC-ELISA results were acceptable, but YFV was infectious at all formalin concentrations 
(data not shown).
YFV, SLEV, POWV, CHIKV, LACV, and JCV were treated with hydrogen peroxide at a 
final concentration of 3%. The VSAA decreased and was unacceptable in the MAC-ELISA 
compared to untreated virus (data not shown). In addition, infectivity assays of the treated 
material could not be conducted, as the residual hydrogen peroxide was toxic to the Vero 
cells used in both assays (data not shown).
YFV, SLEV, MAYV, and LACV treated with sarkosyl at final concentrations of 0.1% to 
0.3% resulted in unacceptably low VSAA in the MAC-ELISA, and residual infectivity at all 
sarkosyl concentrations (data not shown).
3.2.11. Hydrolysis of BPL—Aliquots of SLEV and CHIKV treated with final 
concentrations of 0.05 and 0.3% BPL were incubated to facilitate the complete hydrolysis of 
BPL. Hydrolyzed versus non-hydrolyzed SLEV samples had similar VSAA and NBR in the 
MAC-ELISA, and both conditions generated usable working SLEV antigen dilutions at 1:10 
(Table 3). In contrast, the VSAA of CHIKV decreased from 1:32 to 1:16 following 
hydrolysis, although the NBR decreased as well.
3.3. Antigen Concentration
In order to evaluate the best method to concentrate antigen to the standardized working 
dilution of ∼1:160, 15 ml of gamma-irradiated YFV antigen was concentrated 10X and 35 
ml of BPL-inactivated SLEV antigen was concentrated 20X by ultracentrifugation or in 
centrifugal filters. Following ultracentrifugation, all of the supernatant was removed and the 
antigen pellet was resuspended in 1.5 ml (YFV) or 1.8 ml (SLEV) final volume of either 
0.1M trizma/BS buffer or 1X PBS. During the centrifugal filter method, the cell culture 
supernatant was centrifuged until the supernatant volume remaining in the filter reached 
approximately the final volume needed to achieve the desired concentration factor. The 
volume was then adjusted to 1.5 ml (YFV) or 1.8 ml (SLEV) with 0.1M trizma/BS buffer or 
1X PBS. The concentration method that resulted in the highest working antigen dilution 
with both VSAA and NBR in the acceptable ranges was selected for future use (Figure 2).
YFV antigen concentrated 10X by ultracentrifugation and resuspended in 0.1M trizma/BS 
buffer or 1X PBS yielded working antigen dilutions of 1:40 and 1:20, respectively; in 
contrast, concentration by centrifugal filters yielded working antigen dilutions of 1:160 and 
1:80, respectively. SLEV antigen concentrated 20X by ultracentrifugation and resuspended 
in 0.1M trizma/BS buffer or 1X PBS yielded working antigen dilutions of 1:40 and 1:10, 
respectively, whereas centrifugal filters yielded working antigen dilutions of 1:80 in both 
buffers. All methods and buffers resulted in acceptable NBR. The centrifugal filter method 
with volume adjustments using 0.1M trizma/BS buffer yielded the highest concentrated 
product. The remaining antigens were then concentrated 5X to 30X by centrifugal filters to 
obtain a standard working antigen dilution of ∼1:160.
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CDC DVBD ADB produces and maintains an inventory of the many arbovirus reference 
antigens used in serological assays. Cell culture has largely replaced the use of animals, and 
inactivation and concentration methods needed to be modified and optimized for cell 
culture. The antigen production process and evaluations of nine arbovirus antigens used in 
the CDC MAC-ELISA, the end-use assay for this study, were described here. There were 
three each from Flaviviridae, Togaviridae, and Bunyaviridae, and they were produced based 
on a prioritized list set by the diagnostic laboratory in the following order: SLEV, YFV, 
CHIKV, JCV, POWV, LACV, TAHV, MAYV, and SINV. Production of each antigen 
proceeded one at a time, from growth curves to finished product, according to the algorithm 
illustrated in Figure 3. During the development of each antigen, modifications were made to 
the methods and the procedure was optimized based on previous antigen production results 
and observations, at times necessitating going back and changing methods and repeating 
evaluations. Although there were trends, and in some cases one method was clearly superior 
to another for all the antigen preparations, such as concentrating the antigen using 
centrifugal filters, in general, the production method needed to be optimized for each virus.
Additionally, antigens were produced in the most inexpensive and time-efficient manner as 
possible, so that if BPL treatment produced an acceptable antigen, gamma-irradiation was 
generally not pursued as a treatment option due to the expense and hands-on time this 
method required. SLEV, MAYV, and SINV were the exceptions in that both BPL and 
gamma-irradiation treatments were performed, even though acceptable antigens were 
produced by BPL. SLEV was one of the first antigens produced, and was included in the 
batch of YFV and CHIKV samples that were gamma-irradiated out of necessity. MAYV and 
SINV were preemptively sent for gamma irradiation treatment because these alphaviruses 
were assumed to behave similarly to CHIKV.
The first step in the production process was to conduct growth curves to determine the best 
virus strain and cell type to use. A second small batch was then produced under the optimal 
conditions and used for inactivation and concentration analyses. Once the inactivation and 
concentration procedure was finalized, a large batch of 2 to 10 T150 cm2 flasks was 
produced, yielding 100–500 vials of antigen.
Initially, titer was the performance indicator during the growth curve analyses and the 
conditions that resulted in the highest titer were assumed to also yield the highest VSAA in 
the MAC-ELISA. However, some inactivated viruses with high titers had low VSAA. In 
order to determine if the antigen degradation was caused by the inactivation procedure, the 
VSAA of the live virus was compared to the inactivated antigen by MAC-ELISA. In some 
cases the VSAA was unacceptably low for both the live and inactivated virus, and the 
highest titers did not necessarily correspond to the highest VSAA. Notably in CHIKV 
antigen production, the third antigen in the sequence, strains 181/25 and S27 both had titers 
of 10.3 log10 PFU/ml in C6/36 cells, but strain 181/25 had acceptable VSAA at a working 
antigen dilution of 1:4, whereas the VSAA of CHIKV strain S27 was unacceptable at any 
dilution (Table 2). Thereafter, viral growth curve samples were titrated but also evaluated by 
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MAC-ELISA, and the MAC-ELISA became the primary performance indicator to evaluate 
antigen activity at every step in the production process, including the live virus.
The differences in antigen activity between the two CHIKV strains described above also 
highlight the importance of evaluating a variety of virus strains during the initial growth 
curve evaluation. The prototype strain was generally used during SMB antigen production, 
and this strain was assumed to make the best, most reactive antigen in cell culture as well. 
However, as was demonstrated with JCV and SINV antigen production, the prototype 
strains were not as reactive as some of the non-prototype strains from the reference 
collection. Only SINV strain AUS MRM 39, a non-prototype Australian isolate, reacted 
with the SINV IgM positive control. However, a caveat to this evaluation is that DVBD does 
not have a reference human anti-SINV IgM positive control serum. Instead, an alphavirus-
group reactive mouse/human chimeric monoclonal antibody (cMAb) was used, which may 
have affected the reactivity of the various SINV strains tested (Thibodeaux et al., 2011). A 
SINV IgM-specific positive control from a natural human infection may produce different 
results. Additionally, there were limited positive control reference sera with which to 
evaluate the other antigens as well. Sera from a variety of geographical regions would be 
needed to determine if the difference in reactivity was due to the virus strains.
The cell type the viruses were cultured in also affected titer and antigen reactivity (Figure 1 
and Table 2). Vero cells secrete cell contact inhibition factors which slow cell division and 
maintain the cell monolayer for 7–10 days. (Earley, Johnson, 1988). Thus Vero cells are the 
preferred cell type to culture the slow-growing flaviviruses. Arboviruses such as 
alphaviruses and bunyaviruses, with higher replication rates, are cultured efficiently in 
BHK-21 cells during the exponential growth phase, before the BHK-21 cells reach 
confluency, overgrow, and the cell sheet breaks up. Generally, arboviruses grow well in 
mosquito C6/36 cells, in which they become persistently infected with very little, if any, 
observable CPE. However, the VSAA from supernatant collected from C6/36 cell culture on 
multiple days was shown to be inconsistent and the NBR increased over time. Therefore, 
C6/36 cells were chosen only if the resulting antigen activity was clearly superior to that of 
the other cell types.
As the growth curves in Figure 1 show, the flaviviruses grew to high titers in Vero cells for a 
longer period of time than in BHK-21 cells, allowing for 2–3 collections of supernatant, 
which increased virus yield. Bunyaviruses replicated equally well in Vero and BHK-21 
cells, but the VSAAs were higher for bunyaviruses grown in BHK-21c.13 cells. 
Alphaviruses also grew to high titers in both Vero and BHK-21 cell culture; however there 
was considerable variability between the VSAAs of the 3 alphaviruses in the different cell 
types. For example, CHIKV strain S27 cultured in BHK-21c.15 cells produced acceptable 
VSAA at a working antigen dilution of 1:4, whereas CHIKV S27 grown in Vero cells was 
unreactive (Table 2). These results illustrate the importance of conducting growth curves in 
a variety of cells to determine the optimal cell type to use in antigen production.
Chemical compounds and radiation have been used to destroy the ability of viruses to infect 
cells, including BPL, formalin, hydrogen peroxide, sarkosyl, aziridine compounds, 
ultraviolet light, and gamma irradiation (Amanna et al., 2012; Brand, Allen, 1970; Brown, 
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2001; Hearn, Dawson, 1961; Hiatt, 1964; Nims et al., 2011; Piret et al., 2002b). For 
inactivated viral vaccines and antigens used as reagents in immunoassays, it is also essential 
that antigenic reactivity is preserved (Sabin, 1943). Because large volumes of over 50 
different antigens are produced at DVBD, virus inactivation methods were needed that 
required little downstream processing such as purification or removal of residue. The 
methods also needed to be effective to inactivate large volumes of live virus, as antigen in 
this procedure is concentrated to a standard working dilution after inactivation, and not 
before, as in other applications.
BPL has been used for inactivation of bacteria, fungi, and viruses, as well as disinfection 
and sterilization, and has been widely used to inactivate viral vaccines and antigens used in 
serological assays (French, McKinney, 1964). BPL is an alkylating agent that modifies the 
structure of nucleic acids and proteins, and can cause DNA-protein cross-linking 
(Bonnafous et al., 2014; Lawrence, 2000; Uittenbogaard et al., 2011). The efficiency of BPL 
is dose-specific and specimen-dependent, as accessibility for BPL molecules is related to a 
diffusion gradient across the viral membrane (French, McKinney, 1964). High BPL 
concentrations are required to reach the most buried parts of the virus, and differences in 
BPL diffusion within the virus may in part explain the differences reported in the literature 
on the BPL concentration required to inactivate a specific virus. Described as the “tailing 
phenomenon,” the bulk of the virus is rapidly inactivated by a small concentration of BPL, 
but a disproportionately larger concentration is required to inactivate the residual active 
virus (French, McKinney, 1964; Logrippo, 1960). Although BPL efficiency depends on the 
corresponding alterations of the viral structures and higher BLP concentrations will 
completely inactivate the virus, over-inactivation by BPL can modify viral proteins, 
resulting in loss or increase of antigenicity (Bonnafous et al., 2014; French, McKinney, 
1964; Uittenbogaard et al., 2011).
DVBD ADB has used BPL to inactivate viruses because it is inexpensive and easy to obtain 
and use. In addition, BPL hydrolyzes in aqueous solution; its activity is self-limiting and 
there is no residual BPL that needs to be removed. However, considerable batch-to-batch 
inconsistency following inactivation by BPL was previously observed. Complete batches 
had been rendered unusable as the antigen appeared to be degraded, resulting in a loss of 
VSAA, or the NBR rose above the acceptable limit. Because of this, the optimal virus 
inactivation method was determined empirically with a range of BPL concentrations. 
Finding the correct concentration of BPL was a balance between using a high enough 
concentration to completely inactivate the virus with no or minimal reduction in VSAA, and 
keeping the NBR within the acceptable range, particularly after concentration. The tailing 
phenomenon was seen during BPL treatment as well (most notably with the alphaviruses), in 
which the inactivation kinetics did not decrease linearly to zero, but tapered off below the 
threshold of detection with persistence of low levels of viable virus particles in 
unconcentrated material; post-concentration, these particles were concentrated above the 
threshold of detection.
YFV treated with increasing doses of BPL resulted in lowered VSAA and increased NBR, 
and at the higher BPL concentrations (0.1%), the NBR of the YFV antigen rose above the 
acceptable limit (Table 1A). In contrast, the NBRs remained low at all BPL concentrations 
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for the remaining flaviviruses, SLEV and POWV (Tables 1B and 1C, respectively). BPL 
was most effective at inactivating the three bunyaviruses. There was minimal loss of VSAA, 
and the NBRs were low and stable, even at the highest concentration of 0.1% BPL (Table 
1G-I). Interestingly, similar to work described previously by French and McKinney, VSAAs 
of some of the viruses studied here increased following BPL treatment, with the greatest 
enhancement seen with CHIKV, MAYV, and LACV (French, McKinney, 1964). 
Presumably, the BPL causes conformational changes in the envelope protein that exposes or 
“opens-up” the antigenic epitopes recognized in the MAC-ELISA (Table 1D, Table 1E, and 
1G, respectively). However, higher concentrations of BPL tended to generate higher NBR, 
most notably for CHIKV and MAYV, as it did with YFV, and lower concentrations did not 
completely inactivate these viruses.
To determine if the NBR was due to residual BPL, the BPL was subjected to complete 
hydrolysis following treatment of SLEV and CHIKV (Table 3). BPL-treated SLEV did not 
have high NBR initially, and hydrolysis had little effect on further lowering NBR. The NBR 
of CHIKV did decrease, but the VSAA also decreased, most likely due to antigen 
degradation after being held at 37°C for an additional 2 h, as has been shown previously 
(French, McKinney, 1964). Whereas the NBR of CHIKV decreased to the acceptable range 
after hydrolysis, this antigen was not concentrated, and the NBR often increases after 
concentration. BPL hydrolysis will be further investigated in BPL-treated YFV and CHIKV 
to determine if the NBR remains in the acceptable range following concentration. Therefore, 
while BPL remained the first-line method of inactivation, additional inactivation methods 
were needed for CHIKV and YFV.
Inactivation by gamma-irradiation has advantages over BPL, as there are no chemicals 
added to the supernatant which might interfere with antigen activity by changing pH or 
causing NBR. In addition, the virus remains frozen throughout the irradiation procedure, 
preventing the degradation of labile viruses, as can occur when these viruses are held at 
higher temperatures for extended periods of time. Unfortunately, the process is expensive 
and a dedicated radiation facility and certified personnel are required, limiting its 
availability. Consequently, gamma irradiation analysis was generally performed on viral 
material for which BPL was an inadequate inactivation method. Gamma irradiation modifies 
nucleic acids by causing base mutations, strand cross-linking, and strand breakage, but also 
generates free radicals and peroxides that can modify the antigenic protein epitopes (Nims et 
al., 2011). Consequently, kill curves, or treatment with radiation doses ranging from 1–6 
Mrad, were performed to determine the dose of radiation needed to completely inactivate the 
virus but not compromise the antigen activity.
Because BPL-treated YFV produced an unacceptable antigen, it was the first to be evaluated 
by gamma irradiation. At the highest dose of 5 Mrad, YFV was completely inactivated and 
there was very low NBR, although some decrease in VSAA did occur. The alphaviruses 
were also treated with gamma-irradiation but there was residual infectivity (1–2 log10 
PFU/ml) at 5–6 Mrad. Similar to BPL treatment, gamma irradiation increased alphavirus 
antigen reactivity, possibly by changing antigen conformation to expose the antigenic 
epitopes by the same mechanism as BPL (Table 1D-F).
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For problematic viruses such as CHIKV, in which BPL treatment resulted in unacceptably 
high NBR and gamma irradiation did not completely inactivate the virus, a combination of 
the two methods proved effective. CHIKV strain S27 was first treated with 5.5 Mrad which 
lowered the titer to ≤2 log10 PFU/ml, and then treated with ≤0.05% BPL, which inactivated 
the virus but did not increase the NBR above the acceptable limit.
None of the other inactivation methods were suitable. Either they did not inactivate the virus 
or the antigen activity was destroyed. Aziridine compounds such as binary ethylenimine 
(BEI) were not evaluated, as BEI did not have any advantages over BPL and vaccines 
inactivated by BEI have been shown to have a short shelf-life of ≤ 2 years (Barteling, 2002).
At DVBD ADB, inactivated antigens are concentrated to a standard working dilution of 
∼1:160 and then aliquoted into vials and lyophilized. In any concentration method there is 
some loss of product, but it should be minimized as much as possible. Centrifugal filters 
yielded higher VSAA and lower NBR compared to ultracentrifugation, as antigen remained 
in the retentate in the centrifugal filter method, whereas there was likely some loss of 
ultracentrifuged pelleted antigen when the supernatant was removed. In addition, the 
ultracentrifuged antigen pellet did not fully re-solubilize in the resuspension buffer. 
Subsequently, centrifugal filters are used to concentrate all antigen preparations, even 
though more hands-on time is required to process large antigen volumes (Figure 2).
Arboviruses are sensitive to acidic conditions, whereas alkaline conditions tend to preserve 
arbovirus viability (Beaty et al., 1995; Brand, Allen, 1970). To optimize the storage buffer, 
concentrated YFV and SLEV antigen were resuspended in two different buffers, 0.1M 
trizma/BS (pH 9.0) and 1X PBS (pH 7.4), and antigen activity was compared. Working 
antigen dilutions tended to be higher when antigens were resuspended in 0.1M trizma/BS 
buffer compared to 1X PBS, suggesting that the more alkaline pH of the 0.1M trizma/BS 
buffer helped contribute to antigen preservation. However, additional experiments would 
need to be performed to determine whether antigen preservation was primarily due to pH or 
whether the actual buffer components contributed as well. A future experiment to help 
discern this may consist of resuspending concentrated antigen in 0.1M trizma/BS with a 
more acidic pH and 1X PBS with a more alkaline pH.
Most concentrated antigens demonstrated higher working antigen dilutions when 
resuspended in 0.1M trizma/BS, although SLEV antigen concentrated by centrifugal filters 
and resuspended in either 0.1M trizma/BS or 1X PBS had equivalent working antigen 
dilutions of 1:80. This lack of difference may be due to the smaller volume of buffer added 
to the retentate following filtration, in contrast to the complete removal of cell culture 
supernatant and buffer exchange that occurred during ultracentrifugation.
Concomitant with recent global arbovirus emergence and re-emergence, there has been an 
increase in demand for arbovirus diagnostic testing and the availability of reagents, both in 
terms of the variety of arboviruses tested as well as the amount of reagents needed. Lack of 
commercial sources for arbovirus antigens has necessitated increased production in the 
DVBD ADB reference laboratory. The development of the cell culture arbovirus antigen 
production algorithm and optimization of the methods and processes will enhance the 
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capacity of the reference laboratory to respond to the changing needs of the diagnostic 
laboratory. In addition, this study illustrates the importance of optimizing the antigen 
production procedure for each virus and evaluating antigen performance in the end-use 
assay at every step in the production process.
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Growth of (A) YFV, (B) SLEV, (C) POWV, (D) CHIKV, (E) MAYV, (F) SINV, (G) 
LACV, (H) JCV, and (I) TAHV in Vero, BHK-21, LLC-MK2, and C6/36 cells. T-150 cm2 
flasks were inoculated with MOIs ranging from 0.0005–0.1 and incubated until CPE was 
visible, for up to 16 days. Underlined conditions indicate the optimal virus strain, cell type, 
and harvest day based on virus titer and/or performance in the MAC-ELISA.
Goodman et al. Page 22














Comparison of ultracentrifugation and centrifugal filter concentration methods. (A) Yellow 
fever virus inactivated by gamma-irradiation was concentrated 10X; (B) St. Louis 
Encephalitis Virus inactivated with BPL was concentrated 20X.
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Arbovirus antigen production algorithm.
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Table 3




SLEV - 0.05% BPL
Hydrolysis No Hydrolysis
VSAA NBR VSAA NBR
1:10 0.852 0.050 0.934 0.048
1:20 0.613 0.048 0.744 0.044
1:40 0.401 0.046 0.499 0.047
CHIKV - 0.3% BPL
1:8 1.472 0.156 1.942 0.512
1:16 0.801 0.096 1.329 0.274
1:32 0.477 0.071 0.740 0.145
Abbreviations: VSAA – virus-specific antigen activity; NBR – nonspecific background reactivity.
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